PTEN deficiency is a common defect in juvenile myelomonocytic leukemia

Leukemia Research

Volumn 33, Issue 5, 2009, Pages 671-677

  Liu, Yunying Lucy ^a   Castleberry, Robert P ^b   Emanuel, Peter D ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Hypermethylation; JMML; Leukemia; PTEN; Rapamycin

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAPAMYCIN; RAS PROTEIN;

ARTICLE; CANCER SCREENING; CLINICAL ARTICLE; COLONY FORMATION; COLONY FORMING UNIT GM; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; JUVENILE MYELOMONOCYTIC LEUKEMIA; MALIGNANT TRANSFORMATION; METHYLATION; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION;

BASE SEQUENCE; BLOTTING, WESTERN; DNA METHYLATION; DNA PRIMERS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; PROMOTER REGIONS, GENETIC; PROTEIN KINASES; PTEN PHOSPHOHYDROLASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIROLIMUS; TRANSCRIPTION, GENETIC;

EID: 61449229442     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.09.036     Document Type: Article

References (59)

1. Vardiman J.W., Pierre R., Imbert M., et al. Juvenile myelomonocytic leukemia. In: Jaffe E.S., Harris N.L., Stein H., and Vardimann J.W. (Eds). Pathology and genetics of tumours of haematopoietic and lymphoid tissues: World Health Organization Classification of Tumours (2001), IARC Press, Lyon 55-57
2. Emanuel P.D., Bates L.J., Castleberry R.P., Gualtieri R.J., and Zuckerman K.S. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 77 (1991) 925-929
3. Freeburn R.W., Gale R.E., Wagner H.M., and Linch D.C. Analysis of the coding sequence for the GM-CSF receptor alpha and beta chains in patients with juvenile chronic myeloid leukemia (JCML). Exp Hematol 25 (1997) 306-311
4. Bollag G., Clapp D.W., Shih S., et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 12 (1996) 144-148
5. Donovan S., See W., Bonifas J., Stokoe D., and Shannon K.M. Hyperactivation of protein kinase B and ERK have discrete effects on survival, proliferation, and cytokine expression in Nf1-deficient myeloid cells. Cancer Cell 2 (2002) 507-514
6. Emanuel P.D. Juvenile myelomonocytic leukemia. Curr Hematol Rep 3 (2004) 203-209
7. Lauchle J.O., Braun B.S., Loh M.L., and Shannon K. Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. Pediatr Blood Cancer 46 (2006) 579-585
8. Li J., Yen C., Liaw D., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 (1997) 1943-1947
9. Steck P.A., Pershouse M.A., Jasser S.A., et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15 (1997) 356-362
10. Li D.M., and Sun H. TEP1 encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 57 (1997) 2124-2129
11. Leslie N.R., and Downes C.P. PTEN function: how normal cells control it and tumor cells lose it. Biochem J 382 (2004) 1-11
12. Chow L.M.L., and Baker S.J. PTEN function in normal and neoplastic growth. Cancer Lett 241 (2006) 184-196
13. Cully M., You H., Levine A.J., and Mak T.W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev 6 (2006) 184-192
14. Auger K.R., and Cantley L.C. Novel polyphosphoinositides in cell growth and activation. Cancer Cells 3 (1991) 263-270
15. Cantley L.C., and Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96 (1999) 4240-4245
16. Gu J., Tamura M., and Yamada K.M. Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J Cell Biol 143 (1998) 1375-1383
17. Weng L.P., Smith W.M., Brown J.L., and Eng C. PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model. Hum Mol Genet 10 (2001) 605-616
18. Platanias L.C. Map kinase signaling pathways and hematologic malignancies. Blood 101 (2003) 4667-4679
19. Gu J., Tamura M., Pankov R., et al. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol 146 (1999) 389-403
20. Comer F.I. Parent CA. PI 3-Kinases and PTEN. How opposites chemoattract. Cell 109 (2002) 541-544
21. Liaw D., Marsh D.J., Li J., et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16 (1997) 64-67
22. Marsh D.J., Dahia P.L., Zheng Z., et al. Germline mutations in PTEN are present in Bannayan-Zonana Syndrome. Nat Genet 16 (1997) 333-334
23. Soria J.C., Lee H.Y., Lee J.I., et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 8 (2002) 1178-1184
24. Kurose K., Zhou X.P., Araki T., Cannistra S.A., Maher E.R., and Eng C. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 158 (2001) 2097-2106
25. Dahia P.L., Marsh D.J., Zheng Z., et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 57 (1997) 4710-4713
26. Zhou X.P., Gimm O., Hampel H., Niemann T., Walker M.J., and Eng C. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 157 (2000) 1123-1128
27. Tashiro H., Blazes M.S., Wu R., et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57 (1997) 3935-3940
28. Dahia P.L., Aguiar R.C., Alberta J., et al. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies. Hum Mol Genet 8 (1999) 185-193
29. Wang S.I., Puc J., Li J., et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 57 (1997) 4183-4186
30. Zhang J., Grindley J.C., Yin T., et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441 (2006) 518-522
31. Niemeyer C.M., Fenu S., Hasle H., et al. Differentiating juvenile myelomonocytic leukemia from infectious disease. Blood 91 (1998) 365-367
32. Miller S.A., Dykes D.D., Polesky H.F., et al. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16 (1988) 1215-1216
33. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93 (1996) 9821-9826
34. Rennie P.S., and Nelson C.C. Epigenetic mechanisms for progression of prostate cancer. Cancer Metastasis Rev 17 (1998) 401-409
35. Chen H., and Wu S. Hypermethylation of the p15(INK4B) gene in acute leukemia and myelodysplastic syndromes. Chin Med J (Engl) 115 (2002) 987-990
36. Teofili L., Martini M., Luongo M., et al. Hypermethylation of GpG islands in the promoter region of p15(INK4b) in acute promyelocytic leukemia represses p15(INK4b) expression and correlates with poor prognosis. Leukemia 17 (2003) 919-924
37. Dahia P.L., FitzGerald M.G., Zhang X., et al. A highly conserved processed PTEN pseudogene is located on chromosome band 9p21. Oncogene 16 (1998) 2403-2406
38. Yu K., Toral-Barza L., Discafani C., et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocrine-Related Cancer 8 (2001) 249-258
39. Bjornsti, and Houghton. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4 (2004) 335-348
40. Yilmaz O.H., Valdez R., Theisen B.K., et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441 (2006) 475-482
41. Ali I.U., Schriml L.M., and Dean M. Mutation spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 91 (1999) 1922-1932
42. Eng C. PTEN: one gene, many syndromes. Hum Mutat 22 (2003) 183-198
43. Stamblic V., MacPherson D., Sas D., et al. Regulation of PTEN transcription by p53. Mol Cell 8 (2001) 317-325
44. Maehama J., O'Kahara F., and Kanaho Y. The tumour suppressor PTEN: involvement of a tumour suppressor candidate protein in PTEN turnover. Biochem Soc Trans 32 (2004) 343-347
45. Trotman L.C., and Pandolfi P.P. PTEN and p53: who will get the upper hand?. Cancer Cell 3 (2003) 97-99
46. Mayo L.D., Donner D.B., and The P.T.E.N. Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci 27 (2002) 462-467
47. Virolle T., Adamson E.D., Baron V., Birle D., Mercola D., Mustelin T., et al. The Egr-1 transcription factor directly activates PTEN during irradiation-induced signaling. Nat Cell Biol 3 (2001) 1124-1128
48. Endersby R., Baker S.J., and Patel T.B. The tumor suppressor PTEN is necessary for human Sprouty 2-mediated inhibition of cell proliferation. J Biol Chem 281 (2006) 4816-4822
49. Patel L., Pass I., Coxon P., Downes C.P., Smith S.A., and Macphee C.H. Tumor suppressor and anti-inflammatory actions of PPARγ agonists are mediated via upregulation of PTEN. Curr Biol 11 (2001) 764-768
50. Chow J.Y., Quach K.T., Cabrera B.L., Cabral J.A., Beck S.E., and Carethers J.M. RAS/ERK modulates TGFbeta-regulated PTEN expression in human pancreatic adenocarcinoma cells. Carcinogenesis 28 (2007) 2321-2327
51. Johannessen C.M., Reczek E.E., James M.F., Brems H., Legius E., and Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA 102 (2005) 8573-8578
52. Emanuel P.D., Bates L.J., Zhu S.W., Castleberry R.P., Gualtieri R.J., and Zuckerman K.S. The role of monocyte-derived hemopoietic growth factors in the regulation of myeloproliferation in juvenile chronic myelogenous leukemia. Exp Hematol 19 (1991) 1017-1024
53. Loh M.L., Vattikuti S., Schubbert S., et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 103 (2004) 2325-2331
54. Birnbaum R.A., O'Marcaigh A., Wardak Z., et al. Nf1 and Gmcsf interact in myeloid leukemogenesis. Mol Cell 5 (2000) 189-195
55. Mohi M.G., Williams I.R., Dearolf C.R., et al. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell 7 (2005) 179-191
56. Weng L.P., Brown J.L., and Eng C. PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum Mol Genet 10 (2001) 599-604
57. Gao T., Furnari F., and Newton A.C. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 18 (2005) 13-24
58. Hafizi S., Ibraimi F., and Dahlback B. C1-TEN is a negative regulator of the Akt/PKB signal transduction pathway and inhibits cell survival, proliferation, and migration. Faseb J 19 (2005) 971-973
59. Recher C., Beyne-Rauzy O., Demur C., et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 105 (2005) 2527-2534